SXTP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -19.15%, SMA50 -6.8%, SMA200 -48.11%). The stock’s 14-day RSI is 42.39 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -83.26% below its high and over 117.65% above its low. Average 10-day trading volume of 51.69 thousand shares is below the 3-month average of 3.68 million, indicating normal recent market interest.

60 Degrees Pharmaceuticals, Inc. generated EPS of -$29.29 over the past year. Five-year average earnings growth is 12.29%. Wall Street analysts project EPS growth of 70.24% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $3.00. The high target offers 1176.6% upside. The low target suggests 59.57% downside. The mean target is $9.00. This offers 378.72% upside. 60 Degrees Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 17.86%. The prior quarter beat by 0.81%. Over the last six quarters, Apple has recorded several small beats. These include 6.82% in August 14, 2024.

60 Degrees Pharmaceuticals, Inc. has 4.10 million shares outstanding. The public float is 3.73 million shares, elevated short interest at 2.50% of float. This equals 101.71 thousand shares. The short ratio is 0.08 days. Institutional investors hold 6.94% of the float. Insiders own 2.5%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

60 Degrees Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.03. This means the shares are trading below this model’s fair value.

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) closed at $3.16 USD, gaining $1.28 (68.09%) from the previous close of $1.88. The stock is currently mid-range between its 52-week high and low $1.36 and $17.68. With a market capitalization of about $2.55 million, 60 Degrees Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.03). Key stats such as the average daily volume over the past year has been around 4.07 million shares, trading with heavier-than-usual volume. Headquartered in Washington, DC, 60 Degrees Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Geoffrey Stuart Dow, the company employs approximately 3 people and listed since July 12, 2023. 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.

60 Degrees Pharmaceuticals, Inc. trades at a P/E ratio of -0.37, slightly below the S&P 500 average, with a price-to-sales ratio of 2.66 and a price-to-book ratio of 0.66 suggesting the stock is closer to book value. The P/FCF stands at -0.37, also above market averages.

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares are flat -1.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows 60 Degrees Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.37. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.00, suggesting 378.72% upside. Our AI forecast model points to short-term weakness (-22.34% over two weeks), a medium-term rise (21.28% over three months), and a longer-term loss (-89.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that 60 Degrees Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -22.34%, with price expected at $1.46 by March 24, 2026, within a range of $0.32 to $2.50 3-Month Outlook: Projected rise of 21.28%, reaching $2.28 by June 08, 2026, with a range of $1.40 to $3.10. 1-Year Outlook: Projected loss of -89.36%, with price at $0.20 by March 10, 2027, within a range of $0.00 to $4.39.